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sis. Late-stage diagnosis was associated with lower median income and lower
provider-to-case ratio. Among all comorbidity conditions, presence of congestive
heart failure, paralysis, renal failure, metastatic cancer, coagulation deficiency,
weight loss, fluid and electrolyte disorders, blood loss anemia, deficiency anemias,
alcohol abuse, pneumococal pneumonia, protein calorie malnutrition, distur-
bances of amino acidmetabolism, brain and other neurological disorders were risk
factors of late-stage diagnosis. CONCLUSIONS: Overall, late-stage diagnosis was
associated with factors that suggest lack of access to care. Although comorbidity is
often associated with increased health care utilization, the association of comor-
bidity with late-stage prostate cancer diagnosis suggests that individuals with sig-
nificant comorbiditymaynot be offered routine prostate cancer screening, and that
focus is directed toward management of presenting health problems rather than
routine cancer screening.
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EFFECT OF TREATMENT DELAYS ON LATE-STAGE PROSTATE CANCER
SURVIVAL
Adunlin GB, Xiao H, Ali AA
Florida A&M University, Tallahassee, FL, USA
OBJECTIVES: To examine whether delay in receiving treatment for late-stage pros-
tate cancer were related to adverse survival outcomes. METHODS: The Florida
Cancer Data Systemwas used to extract information onmen diagnosed with pros-
tate cancer with their demographics, primary health insurance payer at diagnosis,
treatment and all-cause death. Census-tract level socioeconomic status was ex-
tracted from Census 2000 and linked to cancer data. Comorbidity following Elix-
hauser Index and County-level provider-to-case ratio were computed. Overall sur-
vival wasmeasured as the number of days between initiation of first treatment and
death? Descriptive statistics were performed. Log-rank test was conducted to eval-
uate the relationship between predictor variables and survival. Kaplan–Meier esti-
mation was used to generate survival curves. Cox proportional hazards regression
model was used for to produce hazard ratios (HRs) and 95% confidence intervals
after controlling for covariates. RESULTS: Between October 1, 2001 and December
31, 2007, 10330 men, average age of 69 had complete vital status, date of treatment
and survival time greater than zerowere diagnosedwith late-stage prostate cancer
in Florida. Of these, 3331 (32 %) died. Themedianswere 286 days for survival and 39
days between the date of diagnosis and initiation of first treatment. Treatment
delay was more likely to increase survival. Compare to patients in active surveil-
lance, those receiving other treatment options had an increased overall survival.
Patients with comorbidities, diagnosed at older age, or uninsured were more likely
to haveworse survival. Living in a census tract with higher educational attainment
was associated with better overall survival. CONCLUSIONS: Further investigation
is needed to understand the reasons for disparity in prostate cancer survival so that
interventions can be implemented to increase prostate cancer screening. The as-
sociation between changes in patterns of care, and treatment delay need to be
elucidated.
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CANCER DURING PREGNANCY: CLINICAL AND ECONOMIC CHARACTERISTICS
ASSOCIATED WITH INPATIENT CASES IN THE UNITED STATES
Chinthammit C, Skrepnek GH
University of Arizona, College of Pharmacy, Tucson, AZ, USA
OBJECTIVES: To assess clinical characteristics and national charges for maternal
hospitalizations and complications associated with cancers during pregnancy in
the United States. METHODS: This population-based retrospective study of inpa-
tient preterm complications or delivery and economic burden associatedwith can-
cer diagnosed during pregnancy utilized Agency for Healthcare Research andQual-
ity (AHRQ) Healthcare Cost and Utilization Project (H-CUP) Nationwide Inpatient
Sample (NIS) data from 2005-2009. Inclusion criteria included 18 years, any ma-
ternal diagnoses or procedures on record, and any diagnosis of cancer. Descriptive
analyses were conducted to report the most common forms of cancer, complica-
tions of pregnancy, and comorbidities. Generalized linear models including multi-
variate logistic and gamma regressions were employed to assess outcomes of pre-
term births and charges, respectively, based upon patient demographics, primary
payer, hospital characteristics, length of stay, Elixhauser comorbidities, preterm
labor, abnormalities in fetal heart rate/rhythm, and pre-eclampsia/eclampsia.
RESULTS: Overall, 14,190 inpatient cancer discharges in pregnant adults from
2005-2009 were observed. The mean maternal age was 30.36.5 years, with an
average length of stay being 5.07.8 days. The national bill summed to $434 mil-
lion, averaging $31,366 (71,765) per case. The most common cancers were Hodg-
kin’s disease and other lymphomas (27%), breast cancer (15%), leukemias (14%),
genitourinary cancers (14%), and thyroid/endocrine cancers (7%). Some 2,846 full-
term births and 2,140 premature births occurred; 321 inpatient fetal deaths/mis-
carriages were reported. In cases involving births, regression analyses found that
metastatic cancer, solid tumors, and pre-eclampsia/eclampsia were significantly
(p0.05) associated with preterm delivery. Increases in total charges were signifi-
cantly associatedwithmetastatic cancer, chronic blood loss anemia, hypertension,
and fluid/electrolyte disorders. CONCLUSIONS: Some 4986 births were observed
among pregnant adults with cancer during 2005-2009, with a large proportion in-
volving premature delivery. Continued research is warranted concerning theman-
agement and long-term implications of cancer and its treatment upon both moth-
ers and their surviving children.
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ARE QALY GAINS FOR NEW PHARMACEUTICALS INCREASING IN CANCER BUT
NOT OTHER DISEASES?
Thorat T, Chambers JD, Neumann PJ
Tufts Medical Center, Boston, MA, USA
OBJECTIVES: Spending on pharmaceuticals as a proportion of total health care
spending is increasing. It is unclear, however, if this increase is translating into
increases in QALYs relative to standard care over time. Our objectives were to
evaluate incremental QALY gains reported in cost-utility studies published from
2000 through 2010; and to compare the findings for cancer and non-cancer related
pharmaceuticals.METHODS:We used the Tufts Medical Center Cost-Effectiveness
Analysis Registry (www.cearegistry.org) to identify cost-utility ratios for pharma-
ceuticals published from 2000- 2010. We considered incremental QALY gains, pub-
lication year, and source of study funding (drug manufacturer or other), for three
sets of analyses: all pharmaceuticals (n2277); cancer-related pharmaceuticals
(n235); and non-cancer related pharmaceuticals (n2042). We used multivariate
linear regression to evaluate the relationship between incremental QALY gains
(dependent variable) with study publication year (independent variable). We re-
garded p values below the 0.05 level of significance as statistically significant and
values between 0.05-0.1 as weakly significant. RESULTS: Adjusting for source of
study funding, in terms of the relationship between incremental QALY gains and
study publication year: for all pharmaceuticals, the estimated coefficient for pub-
lication year was negative (-0.015; p0.082); for non-cancer related pharmaceuti-
cals the estimated coefficient for publication year was negative, (-0.022, p0.017);
and, for cancer related pharmaceuticals, the estimated coefficient for publication
year was positive (0.069, p0.001). CONCLUSIONS: The results suggest that, in
contrast to the effectiveness of non-cancer related pharmaceuticals; the effective-
ness of cancer-related pharmaceuticals show increasing gains over time. That is,
incremental QALY gains for cancer-related drugs are increasing.
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OBJECTIVES: The aim of this study was to determine survival rate, life expectancy,
quality-adjusted life expectancy (QALE), and prognostic factors of cancer patients
of different organ-systems undergoing prolonged mechanical ventilation (PMV).
METHODS: We used data from the National Health Insurance Research Database
(NHIRD) of Taiwan, year of 1998 to 2007, and linked with the National Mortality
Registry to ascertain the mortality. A random sample of this population was per-
formed, and subjects who had continuously undergonemechanical ventilation for
longer than 21 days were enrolled in this study. We linked our dataset with the
registry of cancer under catastrophic illnesses of NHIRD. The life expectancies of
different organ-systems were estimated using a semi-parametric method with
assuming constant excess hazard and barrowing survival function of general pop-
ulation from the vital statistics of Taiwan. Multivariate proportional hazard model
was constructed to assess the effect of different prognostic factors, including age,
sex, organ-systems, comorbidities, hospital levels, and metastasis. Quality of life
data were taken from a sample of 142 patients under PMV and measured with
EQ-5D, which were classified into partial and poor cognitions. RESULTS: The anal-
ysis of 5138 cancer patients undergoing PMV revealed themedian survival was 1.37
months with a one-year survival rate of 14.3%. Head and neck cancer patients
seemed to survive the longest. The overall life expectancy was 1.21 years with
estimated QALE ranged from 0.16 to 0.36 quality-adjusted life years for patients
with poor and partial cognitions, respectively. Metastatic cancer status, cancer
type of lung and liver significantly predict a shorter survival independently.
CONCLUSIONS:Cancer patientswith PMVhad a poor long termoutcome. Palliative
care should be considered early in these patients with such a condition, especially
when metastasis occurred.
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PRIMARY ANDROGEN DEPRIVATION THERAPY VERSUS RADICAL
PROSTATECTOMY IN SEER-MEDICARE DATASET: A COMPARATIVE
EFFECTIVENESS ANALYSIS OF RETROSPECTIVE COHORTS
Liu J, Shi L, Sartor O, Culbertson R
Tulane University, New Orleans, LA, USA
OBJECTIVES: To examine the comparative effectiveness of primary androgen de-
privation therapy (PADT) and radical prostatectomy (RP).METHODS:Male patients
with localized prostate cancer (T1-T2, N0, M0) were identified in the SEER-Medicare
database from January 1998 to December 2007. Patients were 66-74 years old, with-
out other documented cancers, and had PADT initiation or RP within 6 months
after the first recorded diagnosis of prostate cancer in the dataset. PADT-treated
patients were 1:1 matched to the RP-treated patients via propensity score (PS)
matching. The overall survival from diagnosis to death was analyzed using Cox
proportional hazardmodels; prostate cancer specific survival examined using Fine
and Gray competing riskmodeling. The independent regression variables included
age at diagnosis, race, marital status, census regions, urban residence, clinical
cancer stage, Gleason score, prostate specific antigen level, Charlson comorbidity
index, calendar year at diagnosis, andhospitalization (yes or no), surgery (yes or no)
and outpatient visit (yes or no) during one year baseline period. RESULTS: The
PS-matched sample size was 3432 with mean age of 66.0 years. The baseline char-
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acteristics were comparable between the two cohorts (all p-values0.05). During
median follow-up of 2.95 years, the cumulative incidence of deathwas 304 (17.72%)
among 1716 PADT patients and 94 (5.48%) among 1716 RP patients; 66 (3.85%) and 2
(0.12%) for prostate cancer specific deaths, respectively. The PADT group had
nearly 4 times higher overall mortality risk compared to those using RP (odds ratio
(OR)3.534, 95% confidence interval (CI)2.801-4.464, p0.001). Furthermore, pa-
tients who received PADT had significantly higher prostate cancer specific mortal-
ity compared to those using RP (OR30.875, 95% CI7.535-126.506, p0.001).
CONCLUSIONS: Overall mortality and prostate cancer specific mortality following
PADT were significantly higher compared to those following RP among localized
prostate cancer patients. These data do not support the use of PADT in men with
clinically localized prostate cancer.
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FOR THE VALUE OF INDIRECT TREATMENT COMPARISONS IN SECOND-LINE
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Schwander B1, Chouaid C2, Vergnenegre A3, Bischoff HG4, Nuijten M5, Siebert U6,
Walzer S7
1AiM GmbH - Assessment in Medicine, Research and Consulting, Loerrach, Germany, 2Hôpital
Saint Antoine, Paris Cedex France, 3Hôpital du Cluzeau Centre Hospitalier Universitaire (CHU) de
Limoges, Limoges, France, 4Thoraxklinik Heidelberg GmbH, Heidelberg, Germany, 5Ars Accessus
Medica, Amsterdam (Jisp), The Netherlands, 6UMIT - University for Health Sciences, Medical
Informatics and Technology / ONCOTYROL - Center for Personalized Cancer Medicine, Hall i.T. /
Innsbruck, Tyrol, Austria, 7F. Hoffmann-La Roche Pharmaceuticals AG, Basel, Switzerland
OBJECTIVES: Often new treatment options lack comparisons to treatment options
which already exist on themarket andwhichwere launched several years ago. Due
to such a lack of head-to-head evidence indirect treatment comparisons (ITC) are
increasingly being performed. Although ITC methods are widely accepted, the re-
sults are often interpreted with caution, probably because of their lack of external
validity proven by real clinical studies.METHODS:The first available pivotal phase-
III trials for docetaxel and erlotinib in second-line non-small cell lung cancer
(NSCLC) included best supportive care (BSC) as a comparator which allowed an ITC
of erlotinib versus docetaxel to be performed, applying the Bucher methodology.
The pemetrexed pivotal phase-III trial provided direct evidence vs docetaxel,
which subsequently allowed an ITC of erlotinib vs pemetrexed to be performed.
Later another phase-III trial was published comparing erlotinib vs pemetrexed,
which allowed the ITC of erlotinib vs docetaxel to be re-performed. This trial and a
further recently published phase-III trial directly comparing erlotinib vs docetaxel
or pemetrexed, allowed the external validation of the ITC outcomes. The overall
survival (OS) hazard ratios (HR) were used to produce ITC-OS HRs with 95% confi-
dence intervals (95%CI). RESULTS: Comparing erlotinib versus docetaxel resulted
in an ITC-OS HR of 1.25 (95%CI: 0.76-2.06, p0.381). Using these ITC results to
compare erlotinib to pemetrexed resulted in an ITC-OSHR of 1.26 (95%CI: 0.74-2.15,
p0.392). Re-performing the ITC of erlotinib versus docetaxel resulted in an ITC-OS
HR of 0.95 (95%CI: 0.71-1.28, p0.736). The head-to-head evidence validated those
findingswith anOSHR of 0.96 (95%CI: 0.77-1.21, p0.916) and 0.96 (95%CI: 0.78-1.19,
p0.730), comparing erlotinib vs pemetrexed and erlotinib versus pemetrexed or
docetaxel, respectively. CONCLUSIONS: Recently published clinical head-to-head
evidence has confirmed the appropriateness and validity of ITC findings in second-
line NSCLC.
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TARGETED THERAPY (TT) FOR FIRST LINE TREATMENT OF ADVANCED RENAL
CELL CARCINOMA (RCC): AN INDIRECT COMPARISON META-ANALYSIS (ICMA)
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OBJECTIVES: In the past, interferon (IFN) has proven to be effective in extending
the survival of patients with RCC. New TT, drugs such as Sunitinib (SU), Sorafenib
(SO) and Bevacizumab (BE) have been tested against IFN. Recently, a new studywas
published, comparing a new TT, Pazopanib (PZ) versus placebo (PLA) but not inter-
feron. An important question arose about the relative efficacy of PZ versus other TT
and IFN, given that the control group used was not an active one in the PZ trial.
When head-to-head studies are lacking; an ICMA can help solving the problem of
relative efficacy. Our aim was to perform an ICMA comparing TT. METHODS: We
performed a systematic review, searching for randomized controlled trials that
compared TT against IFN or PLA, or those that compared PLA versus IFN. We
conducted an indirect comparisonmeta-analysis that used PLA as a bridge to com-
pare the different TT. The end point of interest was progression free survival (PFS).
The results are expressed as Hazard Ratio (HR), with the corresponding confidence
interval of 95% (CI). RESULTS:We found 8 randomized controlled trials that fit our
inclusion criteria. The results of the ICMA for PFSwere: PZ versus SU [HR 1.19; CI
0.37 to 3.85]; PZ versus IFN [HR0.59; CI 0.23 to 1.55]; PZ versus SO [HR0.75; CI
0.22 to 2.54]; PZ X BE [HR0.83; CI0.31 to 2.24] CONCLUSIONS: The results showed
that PZ was superior to placebo but not to IFN. The confidence intervals obtained
from the analysis were very wide precluding a definitive conclusion regarding the
relative efficacy of TT, although there was a trend to confirm the superiority of SU.
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OBJECTIVES: Study examined the pattern of chemotherapy and biologic therapy
use by line of treatment in newly diagnosed patients with colorectal cancer (CRC).
METHODS: Patients newly diagnosed with CRC between January 1, 2005 and June
31, 2009 and treated with systemic therapy were identified in a US-based admin-
istrative medical claims (i3 Innovus) database. Six months of patient history with
no prior ICD-9 diagnosis of CRC and 1-year post-index continuous enrollment was
required. Patients were followed from initial CRC diagnosis to death, disenroll-
ment, or June 31, 2010. Chemotherapy and biologic treatments over time were
analyzed to identify lines of therapy and assessed and stratified by line of therapy
(1st, 2nd, 3rd ), subgroup analysis was performed in metastatic CRC. RESULTS: Of
9876 patients, 45% received only 1st line treatment, 35% received 1st and 2nd line
treatment and 20% received 3rd line and beyond. 60% of the study patients were
identified as having metastasis either during the follow up period or at index date.
The 1st line, 43% received an oxaliplatin-based regimen, 5% received an irinotecan-
based regimen, and 46% received 5-FU alone. 2nd and 3rd line settings percentages
of patients treated with irinotecan-based regimens increased from 18% to 43%,
respectively, use of oxaliplatin-based regimens dropped from 42% to 22%, respec-
tively. The proportion of subjects who used bevacizumab doubled from 1st to 3rd
line regimen. Overall, use of cetuximab and panitumumab increased from 2% in
the 1st line to 7%, and 23%, respectively in the 2nd and 3rd  lines of treatment.
CONCLUSIONS: Despite treatment guidelines, a large proportion of patients re-
ceived 5-FUmonotherapy and capecitabine as 1st line treatment even for metaste-
ses. The use of biologics in the first line was present with use in later lines. The use
of EGFR inhibitors increased in the later lines of treatment after FOLFOX and FOL-
FIRI with or without bevacizumab.
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OBJECTIVES: Stage IV CRC patients have varying survival results from multiple
lines of treatment. The objective of this study was to evaluate in a real world
context, the impact of adding a third line of chemotherapy to a stage IV CRC
population. METHODS: The Georgia Cancer Specialist database (2005-2011) was
used. Patients with stage IV colon or rectal cancer and treated with chemotherapy
were followed from initial CRC diagnosis until death, study end or lost to follow-up.
Patientswere stratified into lines and type of protocol for treatments. Kaplan-Meier
curves were used to compare the overall survival results between lines of therapy.
RESULTS: There were 335 patients with confirmed stage IV CRC of which 35%
received one protocol, 27% two protocols, and 38% received three or more proto-
cols. The most common first line agents consisted of FOLFOX with or without
bevacizumab or FOLFIRI with or without bevacizumab. Some single agent 5FU or
5FUwith bevacizumabwas observed in first line. Themost common second agents
were the FOLFOX or FOLFIRI not given in first line. However single agent capecit-
abine, cetuximab and bevacizumab were observed. In third line similar single
agents but more panitumumab and capecitabine combinations were observed. Of
those treated with second line (45) and three or more lines (75). The median sur-
vival was no different between the patients that received second line and those
that went on to a third line (Log-Rank P0.1249). CONCLUSIONS: The addition of
adding a third line to a stage IV population that already received a second line failed
show an association to increase survival. The benefit of adding a third line may
benefit some patients and the particular combination of therapy needs to be ex-
plored in future studies.
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COST-EFFECTIVENESS ANALYSIS OF NILOTINIB VERSUS DASATINIB IN
PATIENTS WITH IMATINIB-RESISTANT OR IMATINIB-INTOLERANT CHRONIC
MYELOID LEUKEMIA (CML)
Niu X, Hay J
University of Southern California, Los Angeles, CA, USA
OBJECTIVES: To compare the economic impact from US societal perspective of
Nilotinib and Dasatinib as second-line therapies in treatment of CML patients with
Imatinib resistance or intolerance by conducting a cost-effectiveness analysis.
METHODS: A Markov simulation model was developed to estimate quality ad-
justed life years (QALYs) and expected costs using data from head-to-head com-
parative clinical trials. Costs in the model included medication cost, hospitaliza-
tion cost, physician fee, laboratory test fee, adverse events cost, and value of
waiting time and were obtained from published literature and government and
organization websites. All costs were adjusted to 2011 US dollars. The treatment
pattern was assumed to be 800mg/day for Nilotinib, or 100mg/day for Dasatinib in
the chronic phase and 140mg/day in the advancedphase. Treatmentwas evaluated
up to progression of the disease, best supportive care and up to death, operating 80
cycles of 3 months. Switching from one product to the other due to severe adverse
eventswas also considered. Sensitivity analyseswere performed to test the robust-
ness of the results. RESULTS: In the base case analysis, the total cost for treatment
with Nilotinib was $150,966, and Dasatinib was $126,672. Patients treated with
Nilotinib gained 0.57more life years, or 0.49moreQALYs, comparedwithDasatinib.
The incremental cost-effectiveness ratio (ICER) for Nilotinib therapy was $49,467/
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